Specialized Pro-Resolving Lipid Mediators in Cystic Fibrosis

被引:23
作者
Philippe, Reginald [1 ]
Urbach, Valerie [1 ]
机构
[1] Inst Necker Enfants Malad, INSERM, U1151, F-75993 Paris, France
关键词
resolvin; lipoxin; cystic fibrosis; TRANSMEMBRANE CONDUCTANCE REGULATOR; BRONCHIAL EPITHELIAL-CELLS; FATTY-ACID-METABOLISM; PSEUDOMONAS-AERUGINOSA; ARACHIDONIC-ACID; AIRWAY INFLAMMATION; LUNG INFLAMMATION; CFTR TRAFFICKING; KAPPA-B; EXPRESSION;
D O I
10.3390/ijms19102865
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
In cystic fibrosis (CF), impaired airway surface hydration (ASL) and mucociliary clearance that promote chronic bacterial colonization, persistent inflammation, and progressive structural damage to the airway wall architecture are typically explained by ion transport abnormalities related to the mutation of the gene coding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) channel. However, the progressive and unrelenting inflammation of the CF airway begins early in life, becomes persistent, and is excessive relative to the bacterial burden. Intrinsic abnormalities of the inflammatory response in cystic fibrosis have been suggested but the mechanisms involved remain poorly understood. This review aims to give an overview of the recent advances in the understanding of the defective resolution of inflammation in CF including the abnormal production of specialized pro-resolving lipid mediators (lipoxin and resolvin) and their impact on the pathogenesis of the CF airway disease.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Specialized pro-resolving mediators: endogenous regulators of infection and inflammation
    Basil, Maria C.
    Levy, Bruce D.
    NATURE REVIEWS IMMUNOLOGY, 2016, 16 (01) : 51 - 67
  • [22] Specialized pro-resolving mediators enhance the clearance of dead cells
    Fredman, Gabrielle
    Khan, Sayeed
    IMMUNOLOGICAL REVIEWS, 2023, 319 (01) : 151 - 157
  • [23] Specialized pro-resolving lipid mediators in gut immunophysiology: from dietary precursors to inflammation resolution
    Albuquerque-Souza, Emmanuel
    Dalli, Jesmond
    CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, 2025, 28 (02) : 96 - 103
  • [24] Lipids in Liver Failure Syndromes: A Focus on Eicosanoids, Specialized Pro-Resolving Lipid Mediators and Lysophospholipids
    Artru, Florent
    McPhail, Mark J. W.
    Triantafyllou, Evangelos
    Trovato, Francesca Maria
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [25] Discovery of specialized pro-resolving mediators marks the dawn of resolution physiology and pharmacology
    Serhan, Charles N.
    MOLECULAR ASPECTS OF MEDICINE, 2017, 58 : 1 - 11
  • [26] Specialized Pro-Resolving Lipid Mediators Regulate Ozone-Induced Pulmonary and Systemic Inflammation
    Kilburg-Basnyat, Brita
    Reece, Sky W.
    Crouch, Miranda J.
    Luo, Bin
    Boone, Andria D.
    Yaeger, Michael
    Hodge, Myles
    Psaltis, Christine
    Hannan, Johanna L.
    Manke, Jonathan
    Armstrong, Michael L.
    Reisdorph, Nichole
    Tighe, Robert M.
    Shaikh, Saame Raza
    Gowdy, Kymberly M.
    TOXICOLOGICAL SCIENCES, 2018, 163 (02) : 466 - 477
  • [27] PCOS: A Chronic Disease That Fails to Produce Adequately Specialized Pro-Resolving Lipid Mediators (SPMs)
    Regidor, Pedro-Antonio
    de la Rosa, Xavier
    Mueller, Anna
    Mayr, Manuela
    Gonzalez Santos, Fernando
    Gracia Banzo, Rafael
    Rizo, Jose Miguel
    BIOMEDICINES, 2022, 10 (02)
  • [28] Bronchoprotective mechanisms for specialized pro-resolving mediators in the resolution of lung inflammation
    Duvall, Melody G.
    Bruggemann, Thayse R.
    Levy, Bruce D.
    MOLECULAR ASPECTS OF MEDICINE, 2017, 58 : 44 - 56
  • [29] The role of specialized pro-resolving mediators in maternal-fetal health
    Elliott, E.
    Hanson, C. K.
    Anderson-Berry, A. L.
    Nordgren, T. M.
    PROSTAGLANDINS LEUKOTRIENES AND ESSENTIAL FATTY ACIDS, 2017, 126 : 98 - 104
  • [30] Understanding the Role of Pro-resolving Lipid Mediators in Infectious Keratitis
    Berger, Elizabeth A.
    ROLE OF BIOACTIVE LIPIDS IN CANCER, INFLAMMATION AND RELATED DISEASES, 2019, 1161 : 3 - 12